论文部分内容阅读
“我们绝不走当初民营企业的‘先积累后转型’的老路,”陈丽晔认为,自主创新是民营企业的生命所在,惟有创新才是民营企业实现蜕变的“突破口”。“如果一个企业的核心技术无法成为世界顶尖的技术,那么这个企业就很难跃升为卓越的企业。”陈丽晔感觉正面临突破口——一项革命性的创新技术:“人体电脉冲导入”将会改变和推动整个核酸疫苗及基因治疗产业的发展。如果不是因为前不久新闻报道的一则消息,“罗氏9月11日宣布收购美国Inovio公司的电脉冲导入的治疗性乙肝和前列腺癌两个DNA疫苗,总价达4.2亿美元及两位数的销售提成。”陈丽晔和她的企业上海塔瑞莎生物技术有限公司不会如此迅速跳入
“We will never take the old private enterprises’ accumulation after the first accumulation,” the old road, “Chen Li Ye believes that independent innovation is the life of private enterprises where only innovation is the transformation of private enterprises ” breakthrough “. ”If a company’s core technology can not be the world’s top technology, then this business is very difficult to rise to excellence. “ Chen Li Ye is facing a breakthrough - a revolutionary innovative technology: ”body electrical pulse into “Will change and promote the development of the entire nucleic acid vaccine and gene therapy industry. If not for a news report not long ago, ”Roche announced on Sept. 11 the acquisition of two DNA vaccines for therapeutic Hepatitis B and Prostate cancer introduced by Inovio’s American Pulse, for a total of $ 420 million and double digits Sales commission. “” Chen Li Ye and her company Shanghai Ta Ruisha Biotechnology Co., Ltd. will not jump so quickly